Targeted SAP conjugates are powerful and specific lesioning agents used in the technique known as Molecular Surgery. The ribosome-inactivating protein, saporin (from the seeds of the plant, Saponaria officinalis) is bound to a targeting agent (anything that is recognized on the cell surface and internalized). The targeted conjugate is administered to cells (in vitro or in vivo). The targeting agent seeks out and binds to its target on the cell surface. The conjugate is internalized, saporin breaks away from the targeting agent, and inactivates the ribosomes which causes protein inhibition and, ultimately, cell death. Cells that do not have the cell surface marker are not affected.
Neurons that express TRPV1 (Transient Receptor Potential Vanilloid 1) are primarily a subset of sensory neurons involved in pain and temperature sensation. TRPV1-Saporin selectively targets and destroys TRPV1-expressing nociceptive neurons, helping researchers dissect pain pathways and develop targeted pain therapies by removing key components of the sensory nervous system. This allows researchers to study pain mechanisms, sensory neuron function, and therapeutic approaches in animal models.
This targeted toxin recognizes cells that express TRPV1 in human and mouse. Anti-TRPV1-SAP is a chemical conjugate of the antibody to TRPV1 and the ribosome-inactivating protein, saporin. Anti-TRPV1-SAP specifically eliminates cells that express TRPV1.
The following control is included for validating the specificity of the beta conjugate: Rabbit IgG-SAP (Cat. #IT-35).
This product is being offered as part of our Beta Testing program. It has saporin activity confirmed, peptide sequences published/confirmed, and/or antibody binding specificity published/confirmed. It has not been characterized or reported in scientific literature. The researcher who first publishes data* will receive a $500 credit for use on ATS products.
*Data subject to review by the scientific team at ATS. See complete details here.